Regulating the promotion of prescription drugs
Many countries are implementing regulations governing pharmaceutical advertising, prohibiting the promotion of prescription-only medicines or products to the general public. These can be advertised only to healthcare providers and pharmaceutical industry professionals.
What this means for delegates and the registration process
The conferences organized by IAS – the International AIDS Society – attract a multidisciplinary and international audience, and the IAS complies with national, European and international laws regulating the marketing of prescription drugs.
To do this, the IAS asks all conference delegates to declare their professional status during the registration process in accordance with the IAS data privacy policy. Delegates are then grouped into three categories: healthcare professional; non-healthcare professional; or industry representative.
Each category is defined as follows:
Healthcare professional
A healthcare professional is any person who is of the medical, dental, pharmacy or nursing professions or any other person who, in the course of their professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product. This includes any official or employee of a government agency or other organization (whether in the public or private sector) who may prescribe, purchase, supply or administer medicinal products, and any employee of a company whose primary focus is healthcare.
Industry representative
An industry representative is any person who is part of pharmaceutical company staff (including agency staff and technical contractors supporting promotional activities online), other than healthcare professionals employed by a pharmaceutical company.
Non-healthcare professional
A non-healthcare professional is any person who is not qualified as a healthcare professional or industry representative as per the above definitions (including wholesalers or distributors of medicinal products, healthcare client organization representatives and media).
For in-person participants, the category you select during registration is indicated on your delegate badge. Clearly identifying healthcare providers and industry representatives enables pharmaceutical sponsors to easily determine who they may target with promotion of prescription medicines. The IAS does not accept any liability for the accuracy of the status printed on the delegate’s conference name badge. If you wish to modify your category, please contact us at hcpstatus@iasociety.org.
What this means for satellite symposia and exhibition content and information
As our audience is multidisciplinary, in accordance with mandatory national, European and international regulations, the IAS does not allow any advertising or promotion of prescription-only medicines or products in satellite symposia and the exhibition or exhibition booths in any format. All satellite symposia and exhibition content and information available to conference participants must not promote any prescription-only medicines or products.
It is the full responsibility of the exhibitors and satellite organizers to ensure that all content and information available to conference participants, as well as all their staff, contractors or agencies they work with, fully comply with any applicable regulations and regulatory frameworks governing prescription advertising.
More information
To learn more about the international regulatory frameworks governing prescription advertising, please click on the following links:
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Code of Practice 2019
- IFPMA Notes for Guidance
- IFPMA Note for Guidance on sponsorship of events and meetings (2026 update)
- Joint Guidance on Virtual and Hybrid International Medical Congresses by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA)
- IFPMA/EFPIA/PhRMA Joint Guidance on Virtual and Hybrid International Medical Congresses: Questions & Answers (Q&A) Introduction
- European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice
Advertising medicinal products in Switzerland
Advertising medicinal products in Switzerland is regulated by Articles 31 and 32 of the Therapeutic Products Act and the Ordinance on Advertising for Medicinal Products. These provisions prohibit advertising prescription-only medicines to the general public and establish requirements for advertising directed at eligible healthcare professionals.
Swissmedic, the Swiss Agency for Therapeutic Products, oversees compliance with medicinal product advertising requirements and publishes guidance on their application. Medicinal products generally require Swissmedic authorization before they can be marketed in Switzerland. Promotional claims must be consistent with the product information approved by Swissmedic; unapproved indications must not be promoted.
scienceindustries, which administers pharmaceutical industry self-regulation in Switzerland, provides the Swiss Pharma Code and the Pharma Cooperation Code. These codes address pharmaceutical promotion and interactions with healthcare professionals, healthcare organizations and healthcare client organizations, including transparency requirements. They implement international industry standards, including those of IFPMA and EFPIA, and supplement applicable Swiss legislation.